First Investigational Drug Therapy For Liver Disease NASH Awaiting FDA Approval: Virginia Commonwealth University
December 07, 2019
December 07, 2019
RICHMOND, Virginia, Dec. 7 [TNSmedicalresearch-The Lancet Journal] -- Virginia Commonwealth University issued the following news:
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with Virginia Commonwealth University is the first to demonstrate the safety and effectiveness of . . .
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with Virginia Commonwealth University is the first to demonstrate the safety and effectiveness of . . .